PartnershipUpdated on 30 April 2026
AT-31 BIO: Leading the immunology shift with next-gen immunosuppressive breakthroughs for complex disorders.
About
AT-31 BIO Lab has developed GJK-012, a novel immunomodulatory substance for use in innovative eye drops to treat dry eye syndrome in patients with Sjögren's syndrome. The global dry eye market exceeds $6 billion annually, with a significant unmet treatment need for Sjögren's patients.
We are seeking partners for collaborative new drug development using GJK-012. If your organization is interested in co-development, clinical research, or licensing opportunities with this water-soluble immunosuppressant, please contact us.
Investment partners
We are seeking a capital partnership to accelerate our pipeline. The intended use of funds includes advancing GJK-012 through clinical trials, expanding our R&D team, and supporting the regulatory submission process. This targeted investment will help us deliver innovative eye care solutions to a substantial, underserved patient population.
New drug co-developers
We are open to joint R&D collaboration to leverage complementary expertise
Big Pharma (M&A)
We wish to discuss out-licensing our lead compound. GJK-012 is protected by a recently filed international patent application (patent-pending), ensuring exclusive rights and commercial advantage for future partners.
Similar opportunities
Project cooperation
Portfolio Company Collaboration: 20/20 OptimEyes Technologies
- Research
- Execution
- Technical
- Biotech, Pharma and Cosmetics
Renaud Jacquemart
CEO at Omnium Global
Burlington, Canada
Partnership
Advancing Clinical-Grade Botanical Therapeutics for Endometriosis
Gianluigi Corsetti
CEO EndOK at EndOK
Rome, Italy
Project cooperation
Seeking scientific research partners for ERC/other grant applications
- Early
- Other
- Research
- Technical
- EU projects
- Nano and Microtechnologies
- Biotech, Pharma and Cosmetics
- Partner looking for consortium
Isabelle M Gorrillot, PhD
Co-founder, CEO at HO2Rx
Doylestown, United States